CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically the Medical - Diagnostics & Research industry. The company pitches itself as a leading, full-service, non-clinical global drug development partner. Its work spans research model technologies, discovery and safety assessment services (both GLP and non-GLP), and manufacturing support products and services, supporting clients from target identification through non-clinical development and product release.

Operations are organized into three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, total revenue was $4.0 billion, with DSA contributing 59.8% of revenue, Manufacturing 19.1%, and RMS 21.1%. The company currently runs more than 120 sites across over 20 countries, giving it a broad geographic footprint in the preclinical CRO and research-model space.

Despite that scale, the current financials do not show a profitable, capital-efficient business. Net margin is -6.0% and ROE is -7.7%. Those figures mean the company is currently losing money and destroying, rather than compounding, shareholder equity. A wide competitive moat would normally show up as positive, stable margins and returns on equity; right now CRL’s numbers suggest its pricing power or cost structure is not strong enough to produce profits. The integrated portfolio and global reach are strategic assets, but they have not translated into durable recent profitability.

Financial posture

Charles River Laboratories carries a $13.7 billion market capitalization, yet its P/E ratio is -58.8. A negative P/E is not a valuation discount in the traditional sense; it simply reflects trailing losses. Paired with a -6.0% net margin and a -7.7% ROE, the valuation is being driven by expectations of future recovery rather than current earnings power.

The stock’s beta is 1.38, meaning it has historically moved roughly 38% more than the overall market in either direction. At the current snapshot, the price is $284.62, well above the 50-day EMA of $231.41, and the RSI is 77.8, a level typically associated with strong near-term momentum. That combination suggests the market has already priced in a meaningful rebound, but it also leaves little room for disappointment relative to the consensus earnings trajectory.

Strategic priorities & outlook

The company’s most recent 10-K filing outlines a clear operational agenda. First, CRL intends to optimize its global footprint by closing or consolidating approximately 12 additional sites over the next two years, primarily within the DSA and RMS segments. That restructuring is the kind of move often used to remove underutilized capacity and lower fixed costs.

Second, Charles River is integrating Discovery Services and Safety Assessment into one overarching DSA organization with a combined sales force and leadership approach. The stated goal is to become the scientific partner of choice by delivering a comprehensive, integrated portfolio that accelerates biomedical research and therapeutic innovation. Third, the company is continuing to seek opportunities to expand its Biologics Testing Solutions service offerings and facilities in the U.S. and Europe.

In January 2026, CRL acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. That acquisition aligns with the broader focus on securing research-model supply chains while expanding service capacity. Whether these moves can convert the present negative margins and ROE into positive returns is the central question for the stock.

Macro & geopolitical exposure

As a Healthcare / Medical - Diagnostics & Research company, Charles River is exposed to several macro and geopolitical forces that affect the broader industry rather than CRL alone.

Regulatory risk is front and center. Non-clinical drug development work is governed by GLP standards and FDA, EMA, and other global health-authority rules. Any tightening of animal-welfare regulations, restrictions on non-human primate imports or exports, or changes to safety-assessment requirements could directly affect operating costs and model availability. Because CRL sources and sells research models globally, trade policy, tariffs, and customs delays for live animals and biological materials are ongoing exposures.

The business is also tied to pharmaceutical and biotechnology R&D budgets, which in turn can be influenced by interest rates, capital-market conditions, and public science funding such as NIH budgets. A stronger U.S. dollar would pressure the translation of overseas revenue from more than 120 international sites, while a weaker dollar could help. Labor costs for specialized scientific staff and commodity costs for animal husbandry are additional margin variables. These factors are characteristic of the industry rather than unique to CRL.

Recent developments

Recent headlines have centered on price action and insider activity. On August 11, 2026, defenseworld.net reported that Charles River Laboratories International (NYSE:CRL) Chief Accounting Officer Michael Gunnar Knell sold 6,645 shares. The same day, defenseworld.net also noted that the stock set a new 52-week high. The juxtaposition of a 52-week high and an insider sale is worth tracking, though insider transactions alone do not determine valuation direction.

On August 10, 2026, zacks.com published “International Markets and Charles River (CRL): A Deep Dive for Investors,” highlighting the company’s global footprint. Earlier, on August 6, 2026, 247wallst.com included CRL in its roundup of Thursday’s top Wall Street analyst research calls, alongside AppLovin, Global Payments, HubSpot, and others. These items confirm the stock has been on traders’ radar heading into late summer.

Earnings behavior & post-earnings drift

Charles River has an impressive recent earnings record. Over the last eight reported quarters, CRL has beaten consensus EPS estimates in all eight quarters, for a 100% beat rate, with an average earnings surprise of 9.3%. The average 5-day price move after earnings across those quarters has been 1.24%, classified as an upward post-earnings drift.

The most recent four quarters show the underlying variability. On August 5, 2026, CRL reported EPS of $3.02 against an estimate of $2.74, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five trading days. On May 7, 2026, EPS of $2.06 beat the $1.96 estimate by 5.1%, yet the stock slid 2.23% the next day and 12.42% over the next five sessions, showing that beats do not always produce immediate gains. On February 18, 2026, a 2.6% surprise ($2.39 vs. $2.33) drove a 3.95% next-day move and a 6.05% five-day move. On November 5, 2025, a 4.7% beat ($2.43 vs. $2.32) resulted in a 1.90% next-day pop and a 2.27% five-day drift.

The next scheduled report is November 4, 2026, before the market open, with the current consensus EPS estimate at $2.97. Given the 100% beat streak, the market’s real expectation may be higher than the printed consensus, but the May 2026 reaction is a reminder that even a beat can be met with selling if guidance or margins disappoint.